SCHEMBL259705

SCHEMBL259705

Cc1cccc(NC(=O)c2ccc(C#N)cc2)c1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.65
KMT2A Q03164 4/20 0.65
RXFP1 Q9HBX9 1/20 0.65
KCNH2 Q12809 2/20 0.64
SCN10A Q9Y5Y9 1/20 0.64
NPC1 O15118 3/20 0.63
RAB9A P51151 3/20 0.63
SMN1; SMN2 Q16637 2/20 0.63
TP53 P04637 1/20 0.63
NFKB1 P19838 1/20 0.63
NFKB2 Q00653 1/20 0.63
RELA Q04206 1/20 0.63
KCNK3 O14649 7/20 0.60
KCNK9 Q9NPC2 3/20 0.60
POLB P06746 1/20 0.60
ALDH1A1 P00352 2/20 0.58
CYP11B1 P15538 1/20 0.58
CYP11B2 P19099 1/20 0.58
LMNA P02545 1/20 0.58
TSHR P16473 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7335241 0.88 PLAU (0.62) MEN1KMT2ARXFP1KCNH2SCN10A
SCHEMBL13719442 0.86 SCN10A (0.67) MEN1KMT2AKCNH2SCN10ANPC1
SCHEMBL19662802 0.85 TP53 (0.68) MEN1KMT2ARXFP1KCNH2NPC1
SCHEMBL259706 0.84 MEN1 (0.77) MEN1KMT2ARXFP1KCNH2NPC1
SCHEMBL4252916 0.84 KCNK3 (0.72) MEN1KMT2ARXFP1KCNH2NPC1
SCHEMBL13210705 0.83 NAMPT (0.66) MEN1KMT2ANPC1RAB9AKCNK3
SCHEMBL31061080 0.82 KCNK3 (0.60) MEN1KMT2ARXFP1KCNK3KCNK9
SCHEMBL3610083 0.82 HPSE (0.67) MEN1KMT2ANPC1RAB9AKCNK3
SCHEMBL6788515 0.82 PTGS1 (0.63) MEN1KMT2ARXFP1NPC1RAB9A
SCHEMBL22699670 0.82 MEN1 (0.61) MEN1KMT2ARXFP1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3757179-A1 INK COMPOSITION FOR INKJET PRINTING, IMAGE FORMING METHOD, AND RECORDED MATERIAL Fujifilm Corporation (JP) 2020-12-30 EP disclosed
EP-3502198-A1 INK FOR INK JET RECORDING, INK JET RECORDING METHOD, INFRARED READING METHOD, AND PRINTED PRODUCT FUJIFILM Corporation (JP) 2019-06-26 EP disclosed
US-8552065-B2 Biarylamide derivative and compositions containing the derivative as an active ingredient CATHOLIC UNIVERSITY INDUSTRY ACADEMY COOPERATION FOUNDATION (KR) 2013-10-08 US disclosed
US-8552065-B2 Biarylamide derivative and compositions containing the derivative as an active ingredient CATHOLIC UNIVERSITY INDUSTRY ACADEMY COOPERATION FOUNDATION (KR) 2013-10-08 US disclosed
US-20120289595-A1 NOVEL BIARYLAMIDE DERIVATIVE AND COMPOSITIONS CONTAINING THE DERIVATIVE AS AN ACTIVE INGREDIENT CATHOLIC UNIVERSITY INDUSTRY ACADEMY COOPERATION FOUNDATION (KR) 2012-11-15 US disclosed
US-20120289595-A1 NOVEL BIARYLAMIDE DERIVATIVE AND COMPOSITIONS CONTAINING THE DERIVATIVE AS AN ACTIVE INGREDIENT CATHOLIC UNIVERSITY INDUSTRY ACADEMY COOPERATION FOUNDATION (KR) 2012-11-15 US disclosed
US-8067586-B2 Fused heteroaryl derivatives ASTELLAS PHARMA INC. (JP) 2011-11-29 US disclosed
US-8067586-B2 Fused heteroaryl derivatives ASTELLAS PHARMA INC. (JP) 2011-11-29 US disclosed
EP-1277738-B1 CONDENSED HETEROARYL DERIVATIVES ASTELLAS PHARMA INC (JP) 2011-03-30 EP disclosed
US-20100137584-A1 FUSED HETEROARYL DERIVATIVES HAYAKAWA MASAHIKO 2010-06-03 US disclosed
US-20100137584-A1 FUSED HETEROARYL DERIVATIVES HAYAKAWA MASAHIKO 2010-06-03 US disclosed
US-20100137585-A1 FUSED HETEROARYL DERIVATIVES HAYAKAWA MASAHIKO 2010-06-03 US disclosed
US-20100137585-A1 FUSED HETEROARYL DERIVATIVES HAYAKAWA MASAHIKO 2010-06-03 US disclosed
US-20070037805-A1 Fused heteroaryl derivatives HAYAKAWA MASAHIKO 2007-02-15 US disclosed
US-20070037805-A1 Fused heteroaryl derivatives HAYAKAWA MASAHIKO 2007-02-15 US disclosed
US-7173029-B2 Fused heteroaryl derivatives ASTELLAS PHARMA INC. (JP) 2007-02-06 US disclosed
US-7173029-B2 Fused heteroaryl derivatives ASTELLAS PHARMA INC. (JP) 2007-02-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137584-A1 FUSED HETEROARYL DERIVATIVES PIK3CD, PIK3R3, PIK3C2A MEN1 3330/4885KMT2A 1722/4885RXFP1 4866/4885
US-20120289595-A1 NOVEL BIARYLAMIDE DERIVATIVE AND COMPOSITIONS CONTAINING THE DERIVATIVE AS AN ACTIVE INGREDIENT TYR, MITF, MC1R MEN1 502/4885KMT2A 79/4885RXFP1 4787/4885
US-20070037805-A1 Fused heteroaryl derivatives PIK3CD, PIK3R3, PIK3C2A MEN1 3330/4885KMT2A 1722/4885RXFP1 4866/4885
US-20100137585-A1 FUSED HETEROARYL DERIVATIVES PIK3CD, PIK3R3, PIK3C2A MEN1 3330/4885KMT2A 1722/4885RXFP1 4866/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.